Larvol Delta - Alzamend-Neuro-Submits-IND-Application-for-Phase-IIIA-Trial-for-an-Immunotherapy-ALZN002-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimers-Type

ALZN002 - Alzamend Neuro

https://www.businesswire.com/news/home/20220929005339/en/Alzamend-Neuro-Submits-IND-Application-for-Phase-IIIA-Trial-for-an-Immunotherapy-ALZN002-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimer%E2%80%99s-Type

Sep 29, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next